Literature DB >> 27084002

Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.

Hsin-Yu Liu1, Chang-Hao Yang1, Chung-May Yang1, Tzyy-Chang Ho1, Chang-Ping Lin1, Yi-Ting Hsieh2.   

Abstract

PURPOSE: To compare the efficacy of half-dose vs half-time photodynamic therapy (PDT) guided by fluorescein angiography (FA) for the treatment of central serous chorioretinopathy (CSC).
DESIGN: Two-center, retrospective, comparative case series.
METHODS: Sixty-one eyes with acute or chronic CSC involving fovea were recruited; 35 eyes received half-dose PDT and 26 eyes received half-time PDT. Improvement in best-corrected visual acuity (BCVA), resolution of subretinal fluid (SRF) demonstrated by optical coherence tomography (OCT), and recurrence of CSC after PDT were compared between the 2 groups.
RESULTS: The mean follow-up time after PDT was 14.8 ± 13.3 months. Both groups showed significant improvement in BCVA at months 1, 3, 6, and 12 after PDT (P < .05 for all times). Multiple regression analysis showed that PDT type was not correlated with visual improvement (P > .05 for all times). All eyes that received half-time PDT showed complete resolution of SRF within 6 months after PDT, but 3 eyes that received half-dose PDT had persistent SRF before loss to follow-up at months 5, 7, and 8 (P = .21 between 2 groups). Three of 32 eyes in the half-dose group and 2 of 26 eyes in the half-time group had recurrence of CSC during follow-up; all recurrent cases had complete SRF resolution after another PDT treatment. No adverse systemic or ocular side effects were observed in any cases.
CONCLUSIONS: Half-dose and half-time FA-guided PDT were both effective and safe in treating CSC and showed similar efficacy in visual improvement and SRF resolution.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27084002     DOI: 10.1016/j.ajo.2016.04.001

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.

Authors:  Vladimir Sheptulin; Konstantine Purtskhvanidze; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-10       Impact factor: 3.117

2.  Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.

Authors:  Brian E Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2017-05-08

3.  Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.

Authors:  Thomas J van Rijssen; Elon H C van Dijk; Greet Dijkman; Camiel J F Boon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-07       Impact factor: 3.117

4.  Efficacy of Topical Carbonic Anhydrase Inhibitors in Reducing Duration of Chronic Central Serous Chorioretinopathy.

Authors:  Gerald Liew; I-Van Ho; Stephen Ong; Bamini Gopinath; Paul Mitchell
Journal:  Transl Vis Sci Technol       Date:  2020-12-04       Impact factor: 3.283

5.  Genetic factors associated with treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Mayuka Hayashida; Akiko Miki; Shunichiro Nakai; Wataru Matsumiya; Hisanori Imai; Sentaro Kusuhara; Shigeru Honda; Makoto Nakamura
Journal:  Mol Vis       Date:  2020-07-04       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.